产品
编 号：F272898
分子式：C11H16N4O4
分子量：268.27
分子式：C11H16N4O4
分子量：268.27
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 21416-67-1
产品详情
生物活性：
Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC).
体内研究：
Early treatment with Razoxane (30 mg/kg i.p. from day -2 to +14) shows a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation).Animal Model:Sprague-Dawley rats
Dosage:30 mg/kg or 10 mg/kg per day
Administration:Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation
Result:Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.
体外研究：
Razoxane (30 mg/kg; i.p.) exhibits antimetastatic effects in a rat osteosarcoma model.
Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC).
体内研究：
Early treatment with Razoxane (30 mg/kg i.p. from day -2 to +14) shows a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation).Animal Model:Sprague-Dawley rats
Dosage:30 mg/kg or 10 mg/kg per day
Administration:Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation
Result:Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.
体外研究：
Razoxane (30 mg/kg; i.p.) exhibits antimetastatic effects in a rat osteosarcoma model.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备